53 results on '"Coates, A.S."'
Search Results
2. Continuous versus intermittent extended adjuvant letrozole for breast cancer: final results of randomized phase III SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy
3. Observation versus late reintroduction of letrozole as adjuvant endocrine therapy for hormone receptor-positive breast cancer (ANZ0501 LATER): an open-label randomised, controlled trial
4. Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
5. Prognosis of medullary breast cancer: analysis of 13 International Breast Cancer Study Group (IBCSG) trials
6. Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial
7. Long-term results of International Breast Cancer Study Group Trial VIII: adjuvant chemotherapy plus goserelin compared with either therapy alone for premenopausal patients with node-negative breast cancer
8. Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors: Long-term follow up on IBCSG Trial IX
9. Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
10. Adverse prognostic value of peritumoral vascular invasion: is it abrogated by adequate endocrine adjuvant therapy? Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy for early breast cancer
11. Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial
12. The effect of endocrine responsiveness on high-risk breast cancer treated with dose-intensive chemotherapy: results of International Breast Cancer Study Group Trial 15-95 after prolonged follow-up
13. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009
14. Extracapsular tumor spread and the risk of local, axillary and supraclavicular recurrence in node-positive, premenopausal patients with breast cancer
15. Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy?
16. Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial
17. First—select the target: better choice of adjuvant treatments for breast cancer patients
18. Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG)
19. Patients' preferences for adjuvant chemotherapy in early breast cancer: what makes AC and CMF worthwhile now?
20. Meeting Highlights: International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005
21. Timing of CMF chemotherapy in combination with tamoxifen in postmenopausal women with breast cancer: role of endocrine responsiveness of the tumor
22. Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience
23. Tailoring adjuvant treatments for the individual breast cancer patient
24. Comments on the St. Gallen Consensus 2003 on the Primary Therapy of Early Breast Cancer
25. Psychosocial predictors of outcome IV: patients with early-stage breast cancer
26. How to improve timing and duration of adjuvant chemotherapy
27. Quality of life scores predict outcome in metastatic but not in early breast cancer
28. Features that predict responsiveness to chemotherapy and endocrine therapies
29. Randomized controlled trial of ovarian function suppression plus tamoxifen versus the same endocrine therapy plus chemotherapy: is chemotherapy necessary for premenopausal women with node-positive, endocrine-responsive breast cancer? First results of International Breast Cancer Study Group Trial 11–93
30. Psychosocial predictors of survival: Metastatic breast cancer
31. The legacy of Professor Aron Goldhirsch
32. P019 - The timing of ovarian function suppression (OFS) with chemotherapy in premenopausal women with endocrine-responsive HER2-negative early breast cancer: a secondary analysis of TEXT and SOFT
33. PG 0.1 Evolution of the St.Gallen Consensus process for the optimal treatment of women with breast cancer
34. Reply to: Prediction of benefit from chemotherapy in ER-positive/HER2-negative breast cancer
35. 353 Safety of letrozole and tamoxifen monotherapy: updated BIG 1-98
36. Reply to Does the expert panel at the St Gallen meeting provide an unbiased opinion about the management of women with early breast cancer?
37. P107 Anemia during adjuvant chemotherapy for early breast cancer: incidence and risk factors – Results from the International Breast Cancer Study Group (IBCSG)
38. Tailored treatment investigations for premenopausal women with endocrine responsive (ER+ and/or PgR+) breast cancer: The open questions
39. The St Gallen point of view: How do yoy select treatment for “average/high risk” node-negative patients?
40. Survival of patients with visceral metastatic melanoma from an occult primary lesion: A retrospective matched cohort study
41. New treatments for breast cancer: Breakthroughs for patient care or just steps in the right direction?
42. Adding adjuvant CMF chemotherapy to either radiotherapy or tamoxifen: Are all CMFs alike?
43. Quality of life assessment in patients receiving adjuvant therapy for breast cancer: The IBCSG approach
44. The effect of adjuvant prednisone combined with CMF on patterns of relapse and occurrence of second malignancies in patients with breast cancer
45. On the receiving end V: Patient perceptions of the side effects of cancer chemotherapy in 1993
46. Routine tests during follow-up of patients after primary treatment for operable breast cancer
47. Severe vascular adverse effects with thrombocytopenia and renal failure following emetogenic chemotherapy and ondansetron
48. Meta-analysis: The fashion of summing-up evidence: Part II: Interpretations and uses
49. Redressing the balance - The ethics of not entering an eligible patient on a randomised clinical trial: Point of view
50. Metastatic adenocarcinoma of unknown primary site. A randomized study of two combination chemotherapy regimens
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.